Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||
product revenue | 12,880,000 | 12,455,000 | 8,726,000 | 10,730,000 | 8,964,000 | 8,615,000 | 8,189,000 | 7,103,000 | 7,399,000 | 6,712,000 | 5,609,000 | 4,310,000 | 3,516,000 | 3,082,000 | 832,000 | 36,909,000 | 39,118,000 | 31,716,000 | 27,581,000 | 22,674,000 | 19,564,000 | 17,422,000 | 13,727,000 | 9,138,000 | 9,376,000 | 4,465,000 | ||||||||||||||||||||||||
total revenue | 12,880,000 | 12,455,000 | 8,726,000 | 10,730,000 | 8,964,000 | 8,615,000 | 8,189,000 | 7,103,000 | 7,399,000 | 6,712,000 | 5,609,000 | 4,310,000 | 3,516,000 | 5,582,000 | 832,000 | 41,409,000 | 44,045,000 | 34,706,000 | 37,347,000 | 87,098,000 | 35,440,000 | 26,024,000 | 26,221,000 | 30,227,000 | 30,013,000 | 15,198,000 | 40,414,000 | 8,762,000 | 9,799,000 | 11,358,000 | 6,744,000 | 6,268,000 | 6,268,000 | |||||||||||||||||
yoy | 43.69% | 44.57% | 6.56% | 51.06% | 21.15% | 28.35% | 46.00% | 64.80% | 110.44% | 20.24% | 574.16% | -97.99% | -52.46% | 24.28% | 33.36% | 42.43% | 188.15% | 18.08% | 71.23% | -35.12% | 244.98% | 206.29% | 33.81% | |||||||||||||||||||||||||||
qoq | 3.41% | 42.73% | -18.68% | 19.70% | 4.05% | 5.20% | 15.29% | -4.00% | 10.24% | 19.66% | 30.14% | 22.58% | -37.01% | 570.91% | -5.98% | 26.91% | -7.07% | -57.12% | 145.76% | 36.18% | -0.75% | -13.25% | 0.71% | 97.48% | -62.39% | 361.24% | -10.58% | -13.73% | 7.59% | 0.00% | ||||||||||||||||||||
operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||
cost of sales | 1,679,000 | 1,702,000 | 1,085,000 | 1,260,000 | 783,000 | 1,495,000 | 627,000 | 586,000 | 633,000 | 1,108,000 | 554,000 | 413,000 | 517,000 | 435,000 | 339,000 | 706,000 | 959,000 | 638,000 | 675,000 | 533,000 | 287,000 | 393,000 | 303,000 | 334,000 | 702,000 | 695,000 | ||||||||||||||||||||||||
gross profit | 11,201,000 | 10,753,000 | 7,641,000 | 9,470,000 | 8,181,000 | 7,120,000 | 7,562,000 | 6,517,000 | 6,766,000 | 5,604,000 | 5,055,000 | 3,897,000 | 2,999,000 | 5,147,000 | 493,000 | 40,703,000 | 43,086,000 | 34,068,000 | 36,672,000 | 86,565,000 | 35,153,000 | 25,631,000 | 25,918,000 | 29,893,000 | 29,311,000 | 14,503,000 | ||||||||||||||||||||||||
yoy | 36.91% | 51.03% | 1.04% | 45.31% | 20.91% | 27.05% | 49.59% | 67.23% | 125.61% | 8.88% | 925.35% | -98.79% | -52.98% | 22.57% | 32.92% | 41.49% | 189.58% | 19.93% | 76.73% | |||||||||||||||||||||||||||||||
qoq | 4.17% | 40.73% | -19.31% | 15.76% | 14.90% | -5.85% | 16.03% | -3.68% | 20.74% | 10.86% | 29.72% | 29.94% | -41.73% | 944.02% | -5.53% | 26.47% | -7.10% | -57.64% | 146.25% | 37.15% | -1.11% | -13.30% | 1.99% | 102.10% | ||||||||||||||||||||||||||
gross margin % | 86.96% | 86.33% | 87.57% | 88.26% | 91.27% | 82.65% | 92.34% | 91.75% | 91.44% | 83.49% | 90.12% | 90.42% | 85.30% | 92.21% | 59.25% | 98.30% | 97.82% | 98.16% | 98.19% | 99.39% | 99.19% | 98.49% | 98.84% | 98.90% | 97.66% | 95.43% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||||||||||||||
research and development | 86,796,000 | 91,940,000 | 72,743,000 | 82,810,000 | 72,455,000 | 77,401,000 | 68,620,000 | 77,489,000 | 81,841,000 | 68,895,000 | 67,301,000 | 70,298,000 | 64,966,000 | 74,523,000 | 70,123,000 | -142,110,000 | 64,000,000 | 62,007,000 | 41,357,000 | 95,742,000 | 89,555,000 | 90,917,000 | 91,256,000 | 106,248,000 | 101,672,000 | 107,389,000 | 95,585,000 | 93,809,000 | 82,561,000 | 86,730,000 | 78,224,000 | 77,216,000 | 72,917,000 | 79,816,000 | 62,732,000 | 64,678,000 | 60,643,000 | 50,804,000 | 44,038,000 | 36,933,000 | 36,028,000 | 36,423,000 | 32,443,000 | 34,862,000 | 25,526,000 | 22,576,000 | 17,407,000 | 15,279,000 | 14,803,000 | 12,958,000 |
selling, general and administrative | 41,274,000 | 45,869,000 | 41,527,000 | 51,697,000 | 38,537,000 | 35,536,000 | 31,014,000 | 35,305,000 | 25,822,000 | 30,409,000 | 28,367,000 | 32,771,000 | 29,123,000 | 28,264,000 | 31,515,000 | -81,366,000 | 27,152,000 | 29,215,000 | 8,131,000 | 39,778,000 | 34,840,000 | 35,951,000 | 38,501,000 | 34,834,000 | 33,019,000 | 32,390,000 | 31,791,000 | |||||||||||||||||||||||
total operating expenses | 129,749,000 | 139,511,000 | 115,355,000 | 135,767,000 | 111,775,000 | 114,432,000 | 100,261,000 | 113,380,000 | 108,296,000 | 100,412,000 | 96,222,000 | 103,482,000 | 94,606,000 | 113,363,000 | 102,774,000 | 99,929,000 | 90,375,000 | 95,946,000 | 77,555,000 | 80,057,000 | 72,497,000 | 63,448,000 | 54,875,000 | 47,116,000 | 45,955,000 | 45,352,000 | 39,397,000 | 41,363,000 | 30,692,000 | 26,741,000 | 20,695,000 | 18,986,000 | 17,337,000 | 14,794,000 | ||||||||||||||||
income from operations | -116,869,000 | -127,056,000 | -106,629,000 | -125,037,000 | -102,811,000 | -105,817,000 | -92,072,000 | -106,277,000 | -100,897,000 | -93,700,000 | -90,613,000 | -99,172,000 | -91,090,000 | -97,640,000 | -101,145,000 | -68,397,750 | -91,152,000 | -91,222,000 | -92,434,000 | -90,327,000 | -90,196,000 | -43,192,000 | -105,929,000 | -109,060,000 | -113,861,000 | -97,483,000 | -96,356,000 | -99,162,000 | -72,949,000 | -94,012,000 | -90,130,000 | -79,017,000 | -84,600,000 | -67,047,000 | -57,409,000 | -63,512,000 | -56,470,000 | -23,594,000 | -40,898,000 | -40,475,000 | -32,133,000 | -5,195,000 | -26,727,000 | 3,208,000 | -18,330,000 | -12,284,000 | -12,242,000 | -11,069,000 | -8,526,000 | |
yoy | 13.67% | 20.07% | 15.81% | 17.65% | 1.90% | 12.93% | 1.61% | 7.16% | 10.77% | -4.04% | -10.41% | 44.99% | -0.07% | 7.04% | -26.00% | 0.91% | 1.14% | -12.74% | -17.18% | -20.78% | -55.69% | 9.94% | 9.98% | 56.08% | 3.69% | 6.91% | 25.49% | -13.77% | 40.22% | 57.00% | 24.41% | 49.81% | 184.17% | 40.37% | 56.92% | 75.74% | 354.17% | 53.02% | -1361.69% | 75.30% | -57.71% | 118.32% | -128.98% | 114.99% | ||||||
qoq | -8.02% | 19.16% | -14.72% | 21.62% | -2.84% | 14.93% | -13.37% | 5.33% | 7.68% | 3.41% | -8.63% | 8.87% | -6.71% | -3.47% | 47.88% | -24.96% | -0.08% | 2.33% | 0.15% | 108.83% | -59.23% | -2.87% | -4.22% | 16.80% | 1.17% | -2.83% | 35.93% | -22.40% | 4.31% | 14.06% | -6.60% | 26.18% | 16.79% | -9.61% | 12.47% | 139.34% | -42.31% | 1.05% | 25.96% | 518.54% | -80.56% | -933.14% | -117.50% | 49.22% | 0.34% | 10.60% | 29.83% | |||
operating margin % | -907.37% | -1020.12% | -1221.97% | -1165.30% | -1146.93% | -1228.29% | -1124.34% | -1496.23% | -1363.66% | -1396.01% | -1615.49% | -2300.97% | -2590.73% | -1749.19% | -12156.85% | 0% | -209.86% | -260.26% | -241.51% | -49.59% | -298.90% | -419.07% | -434.24% | -322.50% | -321.05% | -652.47% | -180.50% | -1072.95% | -919.79% | -695.69% | -181.52% | -176.60% | -136.02% | |||||||||||||||||
gain on sale of contingent payments | 889,136,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
milestone payment from gain on sale of oncology business | 200,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 13,369,000 | 14,513,000 | 16,087,000 | 18,015,000 | 13,059,000 | 8,120,000 | 8,889,000 | 8,624,000 | 8,375,000 | 8,254,000 | 8,091,000 | 6,488,000 | 3,818,000 | 1,793,000 | 694,000 | 126,000 | 256,000 | -92,000 | 791,000 | 1,115,000 | 1,769,000 | 2,936,000 | 3,579,000 | 2,887,000 | 3,990,000 | 4,405,000 | 4,562,000 | 4,498,000 | 4,204,000 | 3,187,000 | 1,845,000 | 1,880,000 | 1,518,000 | 881,000 | 923,000 | 678,000 | 517,000 | 396,000 | 276,000 | 218,000 | 236,000 | 238,000 | 85,000 | 48,000 | 34,000 | 36,000 | 29,000 | 13,000 | 5,000 | |
other income | 67,000 | 523,000 | 1,253,000 | 1,623,000 | 1,651,000 | 1,579,000 | 1,634,000 | 1,713,000 | 1,198,000 | 1,640,000 | 1,504,000 | 1,357,000 | 1,082,000 | 1,337,000 | 2,973,000 | 2,791,250 | 4,641,000 | 6,524,000 | ||||||||||||||||||||||||||||||||
net income before taxes | -103,433,000 | -105,399,000 | 1,001,035,000 | |||||||||||||||||||||||||||||||||||||||||||||||
income tax expense | -8,876,000 | 53,120,000 | -12,867,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net income | -103,433,000 | -112,020,000 | -89,289,000 | -96,523,000 | 947,915,000 | -96,118,000 | -81,549,000 | -95,940,000 | -91,324,000 | -83,806,000 | -81,018,000 | 36,526,000 | -81,747,000 | -91,806,000 | -94,774,000 | 424,835,500 | -88,766,000 | -86,217,000 | -97,657,000 | -98,979,000 | -90,478,000 | -40,256,000 | -102,350,000 | -106,173,000 | -109,871,000 | -93,078,000 | -91,794,000 | -94,664,000 | -68,745,000 | -90,825,000 | -88,285,000 | -77,137,000 | -83,082,000 | -66,166,000 | -56,486,000 | -62,834,000 | -55,953,000 | -23,198,000 | -40,622,000 | -40,257,000 | -31,897,000 | -4,957,000 | -26,664,000 | 3,704,000 | -18,296,000 | -12,248,000 | -12,382,000 | -11,177,000 | -8,620,000 | |
yoy | -110.91% | 16.54% | 9.49% | 0.61% | -1137.97% | 14.69% | 0.66% | -362.66% | 11.72% | -8.71% | -14.51% | -91.40% | -7.91% | 6.48% | -535.03% | -10.32% | -4.71% | -4.59% | -6.78% | -17.65% | -56.75% | 11.50% | 12.16% | 59.82% | 2.48% | 3.97% | 22.72% | -17.26% | 37.27% | 56.30% | 22.76% | 48.49% | 185.22% | 39.05% | 56.08% | 75.42% | 367.98% | 52.35% | -1186.85% | 74.34% | -59.53% | 115.34% | -133.14% | 112.25% | ||||||
qoq | -7.67% | 25.46% | -7.49% | -110.18% | -1086.20% | 17.87% | -15.00% | 5.05% | 8.97% | 3.44% | -321.81% | -144.68% | -10.96% | -3.13% | -122.31% | -578.60% | 2.96% | -1.34% | 9.40% | 124.76% | -60.67% | -3.60% | -3.37% | 18.04% | 1.40% | -3.03% | 37.70% | -24.31% | 2.88% | 14.45% | -7.16% | 25.57% | 17.14% | -10.10% | 12.30% | 141.20% | -42.89% | 0.91% | 26.21% | 543.47% | -81.41% | -819.87% | -120.24% | 49.38% | -1.08% | 10.78% | 29.66% | |||
net income margin % | -803.05% | -899.40% | -1023.25% | -899.56% | 10574.69% | -1115.71% | -995.84% | -1350.70% | -1234.27% | -1248.60% | -1444.43% | 847.47% | -2325.00% | -1644.68% | -11391.11% | 0% | -221.72% | -285.19% | -242.26% | -46.22% | -288.80% | -407.98% | -419.02% | -307.93% | -305.85% | -622.87% | -170.10% | -1036.58% | -900.96% | -679.14% | -183.60% | -178.32% | -137.52% | |||||||||||||||||
net income per share | -1.78 | -1.93 | -1.55 | -1.72 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 | -1.47 | 0.67 | -1.49 | -1.68 | -1.74 | 6.798 | -1.56 | -1.41 | -1.41 | -1.43 | -1.31 | -0.59 | -1.59 | -1.81 | -1.87 | -1.59 | -1.58 | -1.63 | -1.19 | -1.63 | -1.81 | -1.59 | -1.78 | -1.56 | -1.35 | -1.63 | -1.47 | -0.61 | -1.09 | -1.07 | -0.85 | -0.13 | -0.78 | 0.11 | -0.54 | -0.39 | -0.57 | -0.47 | -2.8 | |
weighted-average number of common shares used in computing net income per share – basic | 58,139,277 | 56,807,415 | 56,939,403 | |||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in computing net income per share – diluted | 58,139,277 | 57,889,255 | 58,432,796 | |||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in computing net income per share – basic and diluted | 57,932,576 | 57,459,195 | 56,802,546 | 56,383,475 | 55,803,663 | 55,604,330 | 55,265,390 | 68,997,879 | 69,144,061 | 68,958,091 | 68,608,279 | 59,994,539 | 58,803,534 | 58,722,244 | 58,453,918 | 57,418,300 | 58,033,386 | 57,721,786 | 55,694,603 | 46,587,631 | 48,459,424 | 46,745,760 | 42,280,525 | |||||||||||||||||||||||||||
milestone revenue | 2,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
royalty income from gain on sale of oncology business | 4,443,000 | 2,704,000 | 2,704,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | 36,526,000 | -81,747,000 | -91,806,000 | -94,774,000 | -64,481,500 | -84,259,000 | -82,790,000 | |||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations, net of tax | 489,317,000 | -4,507,000 | -3,427,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations per share - basic and diluted | 0.67 | -1.49 | -1.68 | -1.74 | -1.033 | -1.48 | -1.36 | |||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations per share - basic and diluted | 7.828 | -0.08 | -0.06 | |||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in computing net income per share from continuing operations, net income from discontinued operations and net income per share – basic and diluted | 54,844,579 | 54,799,680 | 54,555,467 | |||||||||||||||||||||||||||||||||||||||||||||||
cost and expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||
total cost and expenses | 103,222,000 | 101,977,000 | -222,770,000 | 91,152,000 | 91,222,000 | 50,194,000 | 136,479,000 | 125,033,000 | 127,543,000 | 130,290,000 | 141,369,000 | 135,084,000 | 140,082,000 | 127,710,000 | 126,369,000 | 114,360,000 | ||||||||||||||||||||||||||||||||||
gain on sale of oncology business | 999,000 | 1,996,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in computing net income per share from continuing operations, net income per share from discontinued operations and net income per share – basic and diluted | 55,651,487 | 54,789,435 | 57,048,175 | 61,066,977 | ||||||||||||||||||||||||||||||||||||||||||||||
collaboration revenue – related party | 1,350,000 | 1,236,000 | 1,206,000 | 5,735,000 | 60,097,000 | 6,843,000 | 5,516,000 | 8,979,000 | 17,919,000 | 18,183,000 | 8,732,000 | 26,401,000 | 7,345,000 | 8,577,000 | 10,643,000 | 11,346,000 | 10,508,000 | 22,648,000 | 8,985,000 | 6,978,000 | 31,281,000 | 6,218,000 | 5,480,000 | 13,219,000 | 34,202,000 | 8,411,000 | ||||||||||||||||||||||||
collaboration revenue – other | 491,000 | 785,000 | 1,101,000 | 692,000 | 993,000 | 6,060,000 | 420,000 | 812,000 | 970,000 | 230,000 | 12,440,000 | |||||||||||||||||||||||||||||||||||||||
royalty revenue – related party | 2,659,000 | 2,906,000 | 683,000 | 3,339,000 | 3,334,000 | 2,973,000 | 2,666,000 | 2,703,000 | 2,200,000 | 2,224,000 | 2,001,000 | 1,573,000 | 1,417,000 | 1,222,000 | 715,000 | |||||||||||||||||||||||||||||||||||
income from discontinued operations | -8,785,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense for the sale of future revenue | -5,697,000 | -6,014,000 | -9,767,000 | -2,051,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gain on the sale of the oncology business | 1,992,551,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operations, pre-tax | 1,978,069,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
net income from discontinued operations | 1,965,202,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
sales, general and administrative | 20,571,750 | 31,104,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
general and administrative | 26,633,000 | 24,550,000 | 22,713,000 | 17,458,000 | 16,130,000 | 14,823,000 | 15,379,000 | 11,854,000 | 12,644,000 | 10,837,000 | 10,183,000 | 9,927,000 | 8,929,000 | 6,954,000 | 6,501,000 | 5,166,000 | 4,165,000 | 3,288,000 | 3,707,000 | 2,534,000 | 1,836,000 | |||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share – basic and diluted | 39,126,400 | 38,548,153 | 37,956,383 | 37,864,084 | 37,329,220 | 37,214,747 | ||||||||||||||||||||||||||||||||||||||||||||
income before benefit for income taxes | -19,277,500 | -40,257,000 | -26,642,000 | 3,256,000 | -12,213,000 | -11,056,000 | -8,521,000 | |||||||||||||||||||||||||||||||||||||||||||
benefit for income taxes | 22,000 | -448,000 | 169,000 | 121,000 | 99,000 | |||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share – basic | 37,507,298 | |||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share – diluted | 37,507,298 | |||||||||||||||||||||||||||||||||||||||||||||||||
gross collaboration revenue – related party | 12,680,500 | 33,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
cumulative preferred stock dividends | -8,324,000 | 567,000 | -1,798,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net income applicable to common stockholders | -26,664,000 | 3,704,000 | -18,296,000 | -12,248,000 | -20,706,000 | -10,610,000 | -10,418,000 | |||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share applicable to common stockholders – basic | 34,495,076 | |||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share applicable to common stockholders – diluted | 36,592,683 | |||||||||||||||||||||||||||||||||||||||||||||||||
income before benefit from income taxes | -18,296,000 | -12,248,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
benefit from income taxes | ||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares used in net income per share applicable to common stockholders – basic and diluted | 37,429,262 | 33,667,024 | 33,602,472 | 31,394,563 | 15,415,373 | 22,744,486 | 3,722,963 | |||||||||||||||||||||||||||||||||||||||||||
collaboration revenue—related party | 8,411,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
collaboration revenue | 6,744,000 | 6,268,000 | 6,268,000 | |||||||||||||||||||||||||||||||||||||||||||||||
grant revenue |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.